| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.009 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.01 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.01 |